The first scientific publication on 'general adaption syndrome', or as we know today 'biologic
stress' has been published in Nature in 1936 by the 29-year old Hans Selye. His results in …

We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close
participation in Moncada's (maintained vascular integrity, platelets control) homeostatic …

The known effects of a novel stomach pentadecapeptide BPC157 (10 μg or 10 ng/kg),
namely its salutary activity against ethanol (96%, ig)-induced gastric lesions (simultaneously …

BPC 157, a pentadecapeptide with extensive healing effects, has recently been suggested
to contribute to angiogenesis. However, the underlying mechanism is not yet clear. The …

Apart from becaplermin (recombinant human platelet-derived growth factor homodimer of B
chains, PDGF-BB), for the treatment of lower extremity diabetic ulcers, few agents are …

Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in
clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and …

Commonly, the angiogenic growth factors signify healing. However, gastrointestinal
ulceration is still poorly understood particularly with respect to a general pharmacological …

Conceptually, a wide beneficial effect, both peripherally and centrally, might have been
essential for the harmony of brain–gut and gut–brain axes' function. Seen from the original …

Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in
inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, MW 1419, PL 14736) and …

AIM To provide new insights in treatment of colitis and ischemia and reperfusion in rats
using stable gastric pentadecapeptide BPC 157. METHODS Medication [BPC 157, L-NAME …